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ABSTRACT - Purpose. Antibiotics have revolutionized modern medicine, allowing significant progress in 
healthcare and improvement in life expectancy. Development of antibiotic resistance by pathogenic bacteria is a 
natural phenomenon; however, the rate of antibiotic resistance emergence is increasing at an alarming rate, due 
to indiscriminate use of antibiotics in healthcare, agriculture and even everyday products. Traditionally, 
antibiotic discovery has been conducted by screening extracts of microorganisms for antimicrobial activity. 
However, this conventional source has been over-used to such an extent that it poses the risk of “running out” of 
new antibiotics. Aiming to increase access to a greater diversity of microorganisms, a new cultivation method 
with an in situ approach called iChip has been designed. The iChip has already isolated many novel organisms, 
as well as Teixobactin, a novel antibiotic with significant potency against Gram-positive bacteria. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may 
comment by clicking on ABSTRACT on the issue’s contents page. 
  
 
INTRODUCTION 
 
Antibiotics are products of evolutionary selection at 
the microorganism level. These biochemical entities 
have existed in the natural world long before 
Alexander Fleming (1881-1955) had his chance 
encounter with a petri dish of bacterial colonies that 
had been killed by mold contamination in 1928. 
This was the birth of penicillin, derived from the 
Penicillium genus of Ascomycetous fungi, which 
was rightly called a miracle drug. The duo of 
Howard Florey, a pathologist, and Ernst Chain, a 
biochemist, further developed this bactericidal 
substance to increase production efficiency and 
were able to carry out in vivo studies (1).  
 Around 1941, penicillin was being produced 
in large quantities for clinical studies and the results 
were very promising due to the low doses required 
for therapeutic action. The plan was to use 
penicillin to protect soldiers against infections from 
battlefield injuries, and harnessing the full power of 
penicillin required scaling up production (2). Dr. 
Florey and his assistant, Dr. Heatley, came to the 
US to search for new sources of penicillin. Their 
joint effort with the Department of Agriculture led 
to a moldy cantaloupe and the mold, Penicillin 
chrysogeum gave 200 times more penicillin than 
any source that had been tested before (3). The 
discovery of penicillin and its benefits to human-
kind commenced the search for other antibiotics 
present in the natural world. In 1945, Florey and 
Chain shared a Nobel Prize with Alexander 
Fleming for the discovery of penicillin (3). Thus, 
the “Golden Age” of antibiotics started, a period 
from 1950 to 1960, when half of the antibiotics 
commonly used today were discovered (4). 
 Antibiotics are the pillars of modern 
medicine, and have made a significant impact on 
the life expectancy and quality of life, which 
divides the history of medicine to pre- and post-
antibiotic eras (5). The word “antibiotic” refers to a 
chemical substance of microbial origin that inhibits 
growth or obstructs metabolic pathways and are 
used therapeutically to overcome invading 
infections caused by pathogens (6). Its origins are 
from microorganisms themselves, driven by the 
force of natural selection to compete for resources 
with other microorganisms in the microbiome (6). It 
is a wonderful example of evolutionary selection 
arming microorganisms with chemical weapons and 
how this stockpile has been used by humankind as a 
tool against disease causing microbes (5).  
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HUMANS AND MICROORGANISMS 
 
Humans have evolved from single cell ancestors 
and as a species, have grown amongst a world 
teeming with microorganisms. From scalding 
volcanic vents in deep oceans to radioactive 
surroundings, microorganisms not only occupy the 
outside world but also exist in our internal organs, 
such as the GI tract (7,8). Microbiota refers to "the 
ecological community of commensal, symbiotic, 
and pathogenic microorganisms that share our body 
space.” (9) Many of these internal microorganisms 
play an essential role in digesting certain foods, 
assisting in the production of vitamins B & K, and 
protecting the intestinal mucosa by combating other 
aggressive microorganisms (10). The long held 
notion of humans being sterile at birth is also being 
questioned. Aagaard et. al. have found that the 
placenta has its own microbiome, composed of 
nonpathogenic commensal microbiota that closely 
resembles the microbiome of the oral cavity (11). 
Although it is not known whether the placental 
bacteria can reach the developing fetus 
nevertheless, once bacteria colonize the microbiota 
they mature along with us and play a key role in 
ensuring proper digestive function (12). Recent 
mice studies have shown that transplantation of gut 
microorganisms from an obese mouse to a normal 
mouse results in the obesity of the recipient as well 
(13).  
 There are, however, other microorganisms 
that impact human health negatively and are 
collectively termed “pathogenic microorganisms” 
(or simply pathogens). These are microorganisms 
that cause a variety of diseases ranging from mild 
ENT (ear, nose and throat) infections, to life-
threatening meningitis and pneumonia. Along with 
pathogenic bacteria, other microorganisms such as 
viruses, fungi and protozoans can be disease-
causing agents. For this article, we will focus on 
pathogenic bacteria, which are the main targets of 
antibiotic therapy.  
 Bacteria lack a nuclear membrane enclosing 
their genetic material and fall under the Prokaryotic 
domain. From the medical aspect, it is important to 
be able to classify or identify pathogens for proper 
diagnosis and treatment. In 1884, Danish scientist 
Hans Christian Gram, developed a staining 
procedure that differentiated two types of bacteria 
based on the structural differences in their cell walls 
(14). Gram-positive bacteria retain the primary 
crystal violet dye due to the presence of a thick 
peptidoglycan layer. On the other hand, the dye on 
the cell membrane of Gram-negative bacteria is 
washed away with alcohol or acetone due to its 
relatively simple lipopolysaccharide composition. 
The Gram stain might seem like an arbitrary 
criterion used to differentiate bacteria and although 
there are Gram-indeterminate species such as M. 
tuberculosis, the Gram stain does distinguish 
between two fundamentally different kinds of 
bacterial cell wall that determines the overall 
effectiveness of antibiotics on these two classes of 
bacteria. The distinctive feature of Gram-negative 
bacteria is the presence of a unique double 
membrane surrounding each bacterial cell (15). 
This outer membrane is selectively permeable 
thereby preventing certain drugs and antibiotics 
from penetrating the cell. This first line of defense 
coupled with an active efflux system, which pumps 
antibiotics out makes Gram-negative bacteria more 
resistant to antibiotics than Gram-positive bacteria 
(16,17). Certain pathogens such as Pseudomonas 
aeruginosa utilize this efflux mechanism to create 
resistance against fluoroquinolone, a broad-
spectrum antibiotic used to treat a range of Gram-
negative infections. Another mechanism of 
resistance against fluoroquinolone is alteration of 
bacterial targets through gene mutations (18). 
 
ANTIBIOTIC RESISTANCE. 
 
Resistance to the therapeutic effect of antibiotics is 
a growing problem with serious implications to 
human health. It occurs when an antibiotic loses its 
ability to effectively control or inhibit the growth of 
invading bacteria. So, the bacteria continue to 
multiply even when therapeutic levels of the 
antibiotic are present. This is a natural phenomenon 
where selection pressure to survive drives the 
invading pathogens to activate or even devise a 
mechanism to nullify the antibiotic effect (19). Due 
to the unregulated use of antibiotics in agriculture, 
overuse in medicine, and abundance in everyday 
products, we expose microorganisms in the 
environment to a variety of antibiotics (20).  
 There are a number of other ways that 
bacteria develop resistance to antibiotics. Bacteria 
can be naturally resistant to certain antibiotics (i.e. 
they carry genes for resistance; also called “innate 
resistance”), acquire resistance from another 
bacterium, or become resistant due to a genetic 
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mutation. In terms of genetic variability, bacteria 
are relatively flexible with the ability to alter or 
bypass ligands/mechanisms targeted by antibiotics, 
rendering the antibiotic useless. Additionally, 
bacteria are capable of transferring genes through 
conjugation (21). This process involves a bacterium 
transferring its genetic material, which might 
include genes encoding antibiotic resistance. This 
transfer usually occurs within the same species but 
genetic interchange can also happen between 
organisms belonging to the same genus, making 
even more species of microbes resistant to 
antibiotics (22). Bacteriophages can assimilate 
portions of bacterial DNA that might contain 
antibiotic resistance genes into its own genome. The 
bacteriophage can transfer the resistance genes into 
any bacteria that it infects. This process is called 
transduction and has been utilized by researchers to 
endow bacterial cells with genes of interest. 
Moreover, the exceptional growth rate of these 
microorganisms allows them to evolve and adapt 
rapidly to new environmental conditions (23).  
 Antibiotics are extremely important to the 
health care system, critical in preventing post-
operative infection. Without antibiotics, modern 
medicine could not have progressed to its present 
state. But we now face a new challenge: the overuse 
of antibiotics which leads to rise of highly resistant 
bacteria. A 2013 report from the Center for Disease 
Control (CDC) on antibiotic resistance threats in the 
US shows that 50% of all the antibiotics prescribed 
for people are not needed or not optimally effective 
as prescribed. It is a dilemma faced by physicians, 
when patients display symptoms of an infection 
caused by an indeterminate pathogen. Should the 
physician wait for diagnostic test results that may 
take a few days? Or would prescribing an antibiotic 
be more prudent? Faster diagnostic capability 
would greatly decrease antibiotic prescriptions that 
are given in a “just-in-case” scenario. Identification 
of the invading pathogen would further help in 
selecting between a broad-spectrum antibiotic and a 
specific/narrow spectrum antibiotic. In hospitals, 
immunosuppressed patients are more susceptible to 
infections and, thus, often require the aid of 
antimicrobials. The extensive use of antimicrobials 
and close contact among vulnerable patients creates 
a conducive environment for the spread of 
antimicrobial-resistant germs (24,25). Patient 
misuse of antibiotics has also contributed to 
antibiotic resistance (26). It is of utmost importance 
to follow the prescribed antibiotic prescription. If 
the full course is not completed, a some population 
of pathogens can survive the incomplete antibiotic 
treatment, have the opportunity to become 
resistance against the prescribed antibiotic and 
require stronger antibiotics in the future (27).  
 Antibiotic overuse in agriculture, especially 
in livestock, is also a cause for concern. The meat 
industry has transformed immensely over the 
decades with large corporations taking over farms 
and applying an unethical business model to the 
industry. There are 9 billion animals produced for 
food in the U.S. every year (28), the majority of 
which are raised in concentrated animal-feeding 
operations (CAFOs) and given regular doses of 
antibiotics. It is logical to think that livestock need 
to be treated with antibiotics when there is an 
infection; however, 80% of those antibiotics are 
being used non-therapeutically as metaphylaxis or 
growth promotion (29).  
 An accidental discovery in 1948 by scientists 
at Lederle Laboratories showed that the animals 
receiving sub-therapeutic doses of antibiotic in their 
feed seemed to grow faster than others (30). Mixing 
antibiotics in animal feed complemented the goals 
of CAFOs, which is to make their animals grow 
faster and to prevent diseases/infections that may 
reduce production. By putting antibiotics in the 
animal feed, we have developed a misconception 
that livestock can be raised in deplorable, 
unsanitary, and unhealthy conditions. For a while, 
the industry continued adding penicillins and 
tetracyclines to their animal feed, previously known 
as growth promotion, now termed feed efficiency. 
However, this method of adding antibiotics to 
animal feed is being re-examined because of its 
contribution to antibiotic resistance. There are risks 
associated with adding antibiotics to animal feed for 
extended periods of time. Eventually, the animals 
begin to retain the antibiotic-resistant strains of 
bacteria and can be transmitted to other animals 
(28). People who work on farms and in 
slaughterhouses are at risk of contracting these 
resistant strains (31). Transmission can also occur 
when undercooked or raw meat from animals 
containing resistant bacteria is consumed. Although 
most bacteria do not survive the cooking process, 
there are certain bacterial species that can withstand 
the heat during this process (28).  
 Superbugs are strains of bacteria that are 
resistant to several types of antibiotics. According 
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to the CDC, each year these superbugs infect more 
than 2 million people nationwide, and kill at least 
23,000 patients in the US. On a global scale, the 
superbugs cause 700,000 deaths annually and is 
predicted to rise to 10 million in 2050 (29). In the 
past, the most dangerous superbugs were confined 
to health care settings; however, today, superbugs 
are no longer limited to only hospitals. Some strains 
may be found in the community, infecting even 
healthy individuals (32). Effective antibiotics 
entering the market cannot compete with the rapidly 
evolving pace of bacteria. The CDC is pushing 
hospitals to develop antibiotic stewardship 
programs that educates the staff and ensures that 
antibiotics are only used when necessary. 
Antibiotics should be prescribed only when needed, 
and the proper antibiotic should be used for the 
specific type of bacteria (20). Rapid diagnostic 
testing that reveals results within hours could help 
to ensure that antibiotics are used properly (33). 
The general public also needs to be educated in the 
use of antibiotics and the contribution to rise of 
superbugs when antibiotics are not used prudently. 
There needs to be an overhaul of the current 
antibiotic market to conserve the potency of current 
antibiotics because superbugs do not follow 
geographical boundaries nor discriminate between 
people. When our antibiotics of last resort are 
rendered useless by an unyielding pathogen, it will 
be too late to change our habits. 
 
ANTIBIOTIC DISCOVERY &  
DEVELOPMENT 
 
The drug development process is complex, time-
consuming, and expensive. According to the World 
Health Organization, it can take 12 years to 
discover and develop a new medicine. This venture 
typically costs more than $1.5 billion to complete 
all of the research and development necessary 
before the drug can be marketed (34). The 
emergence of antibiotic resistance hovers on the 
horizon, as a top public health threat, with 
discovery and development of new antibiotics 
becoming an increasingly daunting task. The 
Waksman platform collapsed around the 70’s, when 
the traditional methods for screening cultures of 
soil-derived organisms for activity against other 
microorganisms yielded the same compounds over 
and over again (35). As the demand for the 
discovery of new antibiotics increased, several 
discovery approaches such as genomics, high-tech 
chemical approaches, and high-throughput 
screening were launched in the 1990s. But the 
number of companies researching antibiotics has 
decreased significantly since then and has a direct 
impact on the number of antibiotics in development. 
With factors such as high attrition rate in clinical 
trials and unattractive economic prospect 
surrounding antibiotics, many pharmaceutical 
companies have ventured to the greener pastures of 
lifestyle drugs that provide a favorable return on 
their investment. 
 Unlike drugs for chronic conditions, 
antibiotics have shorter regiments and new 
antibiotics are hidden away as a measure of last 
resort, only to be used when the available 
antibiotics become ineffective. This causes the 
pharmaceutical companies to lose valuable time 
when they can gain a return on their investment 
before generics arrive in the market. Regulators, 
policy makers, and companies are working together 
to create incentives for antibiotic research by 
streamlining the approval process and rewarding 
pharmaceutical companies by extending patent 
exclusivity. In 2012, Congress passed into law the 
Generating Antibiotic Incentives Now (GAIN) Act 
(34), which extends drug-patent exclusivity for an 
additional five years, requires the FDA to provide 
updated trail guidance, and expedites the FDA-
approval process. A new intravenous antibacterial 
drug, Dalvance was approved in May 2014 after 
receiving expedited review and being designated as 
a Qualified Infectious Disease Product (QIDP) 
under the GAIN Act (36). As of September 2014, 
FDA has granted 59 QIDP designations for 39 
different unique molecules (37). Additionally, there 
has been a proposal put forward by a UK 
government-appointed review team, where 
companies that already have the “highest priority 
antibiotics” in their pipelines would receive a 
“lump-sum” payment thereby delinking profitability 
from sales volumes.  
 Our arsenal of antibiotics that can effectively 
treat bacterial infections is dwindling due to the 
appearance of resistant bacteria (38). Approaches 
such as creating optimized versions of existing 
antibiotics and designing synthetic entities for 
activity against microorganisms have been used, but 
without the discovery of a reliable lead/target pair, 
the chances of acquiring novel antibiotics does not 
seem promising. Natural products have been a 
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major source of antibiotics that work effectively, 
since they have been molded by evolution to work 
on natural targets (5). They are naturally designed 
to penetrate the membrane of target bacteria and 
have the ability to specifically bind to intracellular 
targets. So, exploiting the natural diversity of 
microorganisms is one of the most viable methods 
to discover novel chemicals that might yield new 
antibiotics to combat resistant pathogens. But 
throughout the history of microbiology, we have 
only been able to culture a small fraction of the 
diverse microbiological population for our own 
purposes, including discovery of antibiotics. An 
overwhelming majority of microbial species has not 
been explored since they do not grow in synthetic 
media in vitro. This has hindered our capability to 
fully exploit the natural microbiological population 
as a source of antibiotics. 
ICHIP TECHNIQUE 
 
Currently, microbiological cultures are grown in 
solid agar-based growth media or in a liquid 
nutrient medium. After introduction of starter 
bacteria into culture they are grown according to 
their nutritional requirements, temperature 
requirements, CO2/O2 optimal concentration, etc. 
However, many bacteria are fastidious, with very 
complex nutritional/environmental requirements 
and culturing such bacteria is challenging (39,40). 
The idea of using synthetic media is still the 
foundation of microbial recovery and propagation. 
Moreover, microbiological techniques have not 
changed over the years compared to the rapid 
progress seen in other sub-fields of biology, such as 
genetics and molecular biology. 
 
 
 
 
 
 Since microorganisms have adapted to thrive 
in their own specific environment, the core idea of 
creating an artificial environment might not be the 
most practical approach for microbial isolation. 
This is apparent when only a fraction of the 
microorganisms from a sample can be cultured in a 
laboratory setting, compared to the high range of 
diversity shown by rRNA and metagenomic studies 
of the same sample (41). Petri-dishes and incubators 
have been the staple methods of microbiology, but 
to actually explore the microbial diversity, a drastic 
change in our strategy of isolation to an in situ 
model might be necessary. A new isolation chip 
(iChip) has been developed by Epstein et al. to 
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grow currently “uncultivable” microorganisms and 
access novel bioactive molecules that might be 
developed as therapeutic antibiotics (Figure 1) (42). 
The iChip applies an in situ cultivation model to 
isolate such inaccessible microorganisms. The 
iChip utilizes a system of hundreds of miniature 
diffusion chambers, each loaded with a single cell. 
The diffusion system allows the cells on the iChip 
interact with naturally occurring nutrients and 
environmental factors (42). This technique has been 
demonstrated to yield a higher number of novel 
microorganisms compared to traditional petri-dish 
methods (50% vs. 1%) (43).  
 The iChips are made of a central hydrophobic 
plastic poloxymethylene (POM) plate with an array 
of holes 1mm in diameter. POM, developed in 1959 
by DuPont as Delrin®, is a thermoplastic
 
which has 
been used as a long-term implant material in cardiac 
valve prostheses, dental implants or joint 
replacement components due to its biocompatible 
properties as well as physical characterisitics (44). 
For the isolation of microorganisms, samples are 
collected from soil or seawater and suspended in 
liquid agar (Figure 1a). The suspension is diluted to 
ensure that one cell is placed per through-hole. The 
liquid agar solidifies and immobilizes the cells in 
the iChip (Figure 1b). Then, polycarbonate 
membranes (pore size of 0.03μm) are applied to 
both sides of the central plate to prevent cell 
migration. Cover plates with matching through-
holes are then screwed to seal the system and hold 
the membrane in place. The whole system is 
designed to prevent cell from escaping; however, it 
allows diffusion of environmental factors. In their 
experiment, Epstein et al. cultured microorganisms 
from seawater and soil samples using the iChip 
system as well as traditional petri- dishes (45). The 
iChips were then returned to the environment from 
where the sample originated for incubation. Using 
microscopy and gene analysis of 16S rRNA to 
identify the microbial species, a higher number of 
colony forming cells were observed in the iChips 
(42). Cells grown in the iChip were different from 
the colonies that were grown in petri-dishes with 
essentially no overlap between the species isolated.  
 The iChip was successful in isolation of novel 
species of bacteria; however, the problem of 
successfully transferring them or sub-culturing 
them to standard petri-dishes still exists. Previous 
studies by Epstein et al. on diffusion chambers, 
which led to the development of iChip, have shown 
success with in vitro domestication. The process of 
in vitro domestication refers to the sub-culturing of 
bacterial isolates, which typically take multiple 
transfers through the diffusion chamber before the 
isolates sustainably grow in standard cultures (46). 
This means that after isolation of “uncultivable” 
microorganisms using iChip, they can be 
domesticated for further exploration of 
antimicrobial potential (42). Using this two-step 
model of i) iChip isolation and then ii) 
domestication to standard culture, we could 
potentially achieve microbial recovery at an order 
of magnitude compared to the level using standard 
cultivation techniques. This allows access to a 
significant number of new species that cannot be 
isolated and grown by traditional in vitro studies 
(45). The iChip is also a practical and robust device. 
The POM can handle temperatures up to 170°C and 
can be autoclaved for sterilization (44). The 
thermoplastic structure has low water absorption 
and is resistant to mechanical abrasion. Moreover, 
the assembly and disassembly of an iChip takes 
under 5 minutes making it usable for massive in situ 
cultivation of environmental microorganisms (47). 
 
TEIXOBACTIN: A NOVEL ANTIBIOTIC 
 
With the iChip, we can access “uncultivable” 
bacteria, discover novel species, and screen them 
for potential antibiotic activity. Among the 10,000 
extracts derived from previously uncultured 
bacteria by iChip, a promising novel antibiotic 
Teixobactin was discovered (5). The source of 
teixobactin was a new species of β-proteobacteria, 
Eleftheria terrae, which belongs to a new genus 
related to Aquabacteria (45). Although aquabacteria 
are not known to produce antibiotics, teixobactin 
showed potent bactericidal activity against Gram-
positive pathogens including multidrug-resistant 
strains (MDR) (47). Teixobactin was also highly 
effective against Mycobacterium tuberculosis, a 
pathogen against which there is a current and urgent 
unmet medical need especially in the developing 
countries (48–51). On a global scale, tuberculosis 
represents the second leading cause of death from 
infectious diseases (52) 
 From a structural viewpoint (Figure 2), 
teixobactin is a depsipeptide with a molecular mass 
of 1,242 Daltons (5). Examination of S. aureus 
cultures treated with teixobactin, and current 
antibiotics, vancomycin and oxacillin showed 
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similar inhibitory effect (Figure 3a-b). Teixobactin 
treatment resulted in dose dependent accumulation 
of the soluble cell wall precursor UDP-MurNAc-
pentapeptide, which was also seen in vancomycin-
treated control cells. Vancomycin blocks a 
membrane-associated step of peptidoglycan 
biosynthesis resulting in cell death (53–55), and 
teixobactin appears to inhibit the same synthesis 
pathway by forming a complex with the precursors 
of peptidoglycan (lipid II) and also teichoic acids 
(lipid III) in the cell wall of Gram-positive bacteria 
(45). Vancomycin binds with terminal D-Ala-D-Ala 
moieties of peptidoglycan precursors and was once 
thought to be “resistance-proof”. Early studies on 
vancomycin in the 1950’s showed that vancomycin 
had ototoxic and nephrotoxic effects but purer 
preparations, retested in the 1970’s showed little or 
no toxic effects. With methicillin resistance 
increasing in staphylococci, vancomycin use 
accelerated worldwide in the 1980’s (56,57). 
 
 
Figure 2.  Structure of Teixobactin 
 
 
 Vancomycin resistant Gram-positive 
Staphylococcus aureus were eventually observed. 
The resistant strains produced enzymes that 
replaced the terminal D-Ala residue with D-lactate 
(D-Lac) or D-serine (D-Ser) and removed high 
affinity targets of vancomycin rendering the 
antibiotic ineffective (58–60). The mechanism of 
teixobactin, which targets invariable domains on the 
precursors, might be a bigger hurdle to resistance 
development.  E. terrae, the producer of 
teixobactin, is a Gram-negative bacteria and does 
not require any significant defensive measures other 
than the lipopolysaccharide cell layer to keep 
teixobactin out of the cell. So, resistance will need 
to originate from some other sources. But 
microorganisms have had millions of years to 
develop resistance to teixobactin, and the possibility 
of resistance genes already existing in nature is 
plausible. Even mutational resistance might arise in 
vivo after prolonged use of teixobactin.  
 In vitro toxicity tests of teixobactin with 
mammalian NIH/3T3 and HepG2 cells showed that 
there was no hemolytic activity or any DNA 
binding at 100 µg/ml. An animal efficacy study was 
also performed in a mouse septicemia model 
infected intraperitoneally with methicillin-resistant 
S. aureus (MRSA) at a dose that leads to 90% death 
(47). One hour post-infection, teixobactin was 
introduced through IV administration at variable 
single doses (1- 20 mg/kg). The results of the 
septicemia model were very encouraging with a 
PD50 (protective dose at which half of the animals 
survive) of 0.2 mg/kg compared to the 2.75 mg/kg 
PD50 of vancomycin. Intentional efforts to raise 
teixobactin-resistant S. aureus or M. tuberculosis by 
exposing the pathogens to sub-MIC (Minimum 
inhibitory concentration) levels of teixobactin for a 
period of 25 days failed to produce resistant 
mutants in vitro (Figure 3d) (5). Teixobactin had 
excellent bactericidal activity against S. aureus, was 
superior to vancomycin in killing late exponential 
phase populations, and retained bactericidal activity 
against vancomycin intermediate S. aureus (VISA) 
(5).  
 In summary, teixobactin stands out as a 
promising candidate to be developed for therapeutic 
use due to its effectiveness against Gram-positive 
bacteria, low toxicity profile, absence of resistance 
and positive results in mice studies but the main 
challenge of clinical trials with humans and 
regulatory hurdles still remain. Novobiotic 
pharmaceutical currently owns the license on 
teixobactin was awarded two NIH NIAID SBIR 
grants in January of 2015. One of the grants is a 
Phase II grant for the “Preclinical Development of 
Teixobactin, a New Antibiotic” (61). 
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Reprinted by permission from Macmillan Publishers Ltc: Nature, A new antibiotic kills pathogens without 
detectable resistance. Jan 2015;517:455–459. 
 
 
SUMMARY 
 
Antibiotics are indispensable tools but have been 
used recklessly throughout their history. Alexander 
Fleming, in his Nobel speech stressed judicious use 
of Penicillin to prevent resistance: 
 
“Then there is the danger that the ignorant 
man may easily under-dose himself and by 
exposing his microbes to non-lethal quantities 
of the drug make them resistant.” 
- Alexander Fleming  
 Nobel lecture, December 11, 1945 
 
 Contrary to Fleming’s advice, sub-therapeutic 
doses of antibiotics have been administered to 
livestock in the guise of growth promotion. Many 
patients are still unaware of the consequences that 
occur when they do not follow proper antibiotic 
therapy. These factors contribute to the rapidly 
increasing resistance against many antibiotics. 
Unfortunately, with the unattractive economic 
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prospects, investment in discovery of new 
antibiotics has dried up. “Running out” of effective 
antibiotics is a terrifying thought; however, it seems 
more like a daunting possibility. Preventing this 
scenario will require judicious use of existing 
antibiotics and revitalization of the dwindling 
investment in antibiotic discovery. The GAIN Act 
is a step in the right direction to incentivize 
pharmaceutical companies to develop antibiotics 
through patent extension and expedited approval 
process. As of December, 2014 there were 37 
antibiotics, with the potential to treat serious or life-
threatening infections, are in clinical trials. At best, 
chances are that only 1 in 5 candidates that enter 
human trails become approved for patients (62). 
 During the Golden Age of antibiotics, almost 
all antibiotics were of bacterial or fungal origin but 
within a few decades all “cultivable” species of 
microorganisms had been over-mined for 
bactericidal compounds. Using the iChip, discovery 
of many novel, previously “uncultivable” microbial 
species  has  been  possible.    It  is  estimated  that 
 
 
Table 1. Potential antibiotics derived from iChip and diffusion chamber isolates 
 
Antibiotic Derived from Potential applications Structure 
Teixobactin Eleftheria 
terrae 
 
 
 
 
 
 
 
 
 
Gram positive microbes 
including Methicillin-
resistant Staphylococcus 
aureus (MRSA) and 
vancomycin-resistant 
enterococci  (VRE) 
 
Neocitreamicin I Nocardia 
species strain  
G0655 
 
Neocitreamicin 
II 
Novo10 Oerskovia 
pauro-
metabola 
Ongoing tests for 
antimicrobial and anti-
neoplastic function.  
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currently we can only cultivate 1% of the microbial 
diversity, which means that the remaining 99% has 
never been studied for any bioactive molecules. The 
iChip provides a highly successful platform for 
microbial isolation and expands the pool of 
potential microorganisms that can be the source of 
new antimicrobials, which is critical in our arms 
race against superbugs. For example E. terrae, a 
new species of related to aquabacteria was 
discovered through the iChip technique and extracts 
from E. terrae yielded Teixobactin, a novel 
antibiotic with high effectiveness against Gram-
positive bacteria. But iChip is not able to recover all 
of the microbial species from a sample. Isolation of 
a novel species by iChip is scarcely enough for 
advanced studies and consequent in vitro 
domestication reduces the microbial recovery rate 
to 10%, which is still an order of magnitude higher 
than the recovery rate using traditional methods. In 
addition to future antibiotics that may result from 
novel species derived from iChip, there may be 
other beneficial ways in the pharmaceutical, 
biofuel, and renewable chemical production field 
where we could utilize new species of bacteria. 
 Exploiting the population of uncultured 
bacteria is likely to revive the Waksman platform of 
antibiotic discovery. Along with Teixobactin, the in 
situ isolation approach has helped discover other 
novel antibiotics such as Neocitreamicin I and II.  
With the help of the diffusion chamber, an earlier 
prototype of iChip, a novel Nocardia strain, the 
producer of neocitreamicins was isolated from a 
soil sample of Falmouth, Massachusetts. The 
neocitreamicins showed in vitro activity against 
Gram-positive bacteria including MRSA and VRE 
(63). Novobiotic pharmaceuticals also holds patent 
for Novo10, an antibiotic candidate with potential 
anti-neoplastic properties. Novo10 is derived from 
Oerskovia paurometabola a Gram positive 
anaerobe, isolated from soil sample collected in 
Gloucester, Massachusetts using a diffusion 
chamber (64). The iChip and its prototype, the 
diffusion chamber, have discovered many novel 
species and bioactive molecules. Teixobactin, 
neocitreamicins and Novo10 are the best candidates 
among many others found in isolate extracts for 
antibiotic activity. The main goal of iChip is to 
increase microbial recovery rate, which will lead to 
the discovery of novel species that were considered 
“uncultivable”. This hidden diversity of 
microorganisms gives us better chances of finding 
novel and natural antibiotics. But the challenge of 
iChip being accepted into isolation/culturing 
practices still remains. The iChip’s portability, 
robustness and simplified use allows the possibility 
of microbial isolation from diverse environments. 
Over the years metagenomics has been utilized to 
discover microbial communities in a culture-
independent analysis (65). In addition to finding 
microbial community composition, metagenomics 
can be applied as a targeted approach to screen 
functional DNA fragments or global gene 
expression. This “shotgun” approach of finding 
novel microbes among the “uncultivable” bacteria 
can now be highly precise by using single cell 
genomics on iChip isolates. Teixobactin will 
probably receive Qualified Infectious Disease 
Product (QIDP) designation under the GAIN Act, 
21 U.S.C § 355 (f)(1)(c) provisioned for multi-drug 
resistant tuberculosis (66). But there will still be 
years of challenges, intense research and clinical 
trials before teixobactin appears as an approved, 
commercial product 
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